PXMTF (PHAXIAM Therapeutics) Cyclically Adjusted PB Ratio: (As of Jun. 30, 2026)


PXMTF PHAXIAM Therapeutics SA PXMTF
38 GF Score
Price $0.00
View Full Analysis

What is PHAXIAM Therapeutics Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


PHAXIAM Therapeutics  (OTCPK:PXMTF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


PHAXIAM Therapeutics Cyclically Adjusted PB Ratio Related Terms


PHAXIAM Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for PHAXIAM Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PHAXIAM Therapeutics Cyclically Adjusted PB Ratio Chart

PHAXIAM Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.48 0.08

PHAXIAM Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.08 0.00 0.00

PXMTF vs VRTX, REGN, SGEN: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, PHAXIAM Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PHAXIAM Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PHAXIAM Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where PHAXIAM Therapeutics's Cyclically Adjusted PB Ratio falls into.


PXMTF
38GF Score
PHAXIAM Therapeutics SA PXMTF
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PHAXIAM Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

PHAXIAM Therapeutics's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec22 is calculated as:

For example, PHAXIAM Therapeutics's adjusted Book Value per Share data for the fiscal year that ended in Dec22 was:

Adj_Book=Book Value per Share/CPI of Dec22 (Change)*Current CPI (Dec22)
=7.413/114.1600*114.1600
=7.413

Current CPI (Dec22) = 114.1600.

PHAXIAM Therapeutics Annual Data

Book Value per Share CPI Adj_Book
201312 31.020 99.800 35.483
201412 59.293 99.860 67.784
201512 59.909 100.040 68.365
201612 39.781 100.650 45.121
201712 110.612 101.850 123.981
201812 85.340 103.470 94.157
201912 48.978 104.980 53.261
202012 14.878 104.960 16.182
202112 7.692 107.850 8.142
202212 7.413 114.160 7.413

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


PHAXIAM Therapeutics Business Description

Address 60 Avenue Rockefeller, Lyon, FRA, 69008
PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.
38GF Score

Get the complete analysis for PXMTF

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price